Trevi TherapeuticsTRVI
About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Employees: 26
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
8.47% more ownership
Funds ownership: 74.87% [Q1] → 83.34% (+8.47%) [Q2]
2% less capital invested
Capital invested by funds: $178M [Q1] → $175M (-$3.18M) [Q2]
4% less funds holding
Funds holding: 80 [Q1] → 77 (-3) [Q2]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
HC Wainwright & Co. Oren Livnat 70% 1-year accuracy 16 / 23 met price target | 84%upside $6 | Buy Reiterated | 22 Oct 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 544%upside $21 | Buy Maintained | 21 Oct 2024 |
B. Riley Securities Mayank Mamtani 48% 1-year accuracy 10 / 21 met price target | 84%upside $6 | Buy Reiterated | 7 Oct 2024 |
Needham Serge Belanger 53% 1-year accuracy 58 / 110 met price target | 145%upside $8 | Buy Reiterated | 4 Oct 2024 |
EF Hutton Jason Kolbert 39% 1-year accuracy 22 / 56 met price target | 544%upside $21 | Buy Maintained | 4 Oct 2024 |
Financial journalist opinion
Based on 5 articles about TRVI published over the past 30 days
